Results 1 to 10 of about 410,054 (119)
MMW - Fortschritte der Medizin, 2021 AbstractLipoprotein(a) [Lp(a)] is an atherogenic lipoprotein with a strong genetic regulation. Up to 90% of the concentrations are explained by a single gene, theLPAgene. The concentrations show a several-hundred-fold interindividual variability ranging from less than 0.1 mg/dL to more than 300 mg/dL. Lp(a) plasma concentrations above 30 mg/dL and even
openaire +4 more sources
Lipoprotein (a): Recent Updates on a Unique Lipoprotein [PDF]
Current Atherosclerosis Reports, 2021 Genetic, epidemiological, and translational data indicate that Lipoprotein (a) [Lp(a)] is likely in the causal pathway for atherosclerotic cardiovascular diseases as well as calcification of the aortic valves.Lp(a) is structurally similar to low-density lipoprotein, but in addition to apolipoprotein B-100, it has a glycoprotein apolipoprotein(a) [apo(a)
Anum Saeed +2 more
openaire +2 more sources
Lipoproteins and Atherosclerosis [PDF]
Journal of Gerontology, 1951 Author(s): Gofman, John W.; Lindgren, Frank T.; Jones, Hardin B.; Lyon, Thomas P.; Strisower, Beverly.
Gofman, John W. +4 more
openaire +3 more sources
Lipoproteins and lipoprotein metabolism in periodontal disease [PDF]
Clinical Lipidology, 2010 A growing body of evidence indicates that the incidence of atherosclerosis is increased in subjects with periodontitis - a chronic infection of the oral cavity. This article summarizes the evidence that suggests periodontitis shifts the lipoprotein profile to be more proatherogenic.
Rachel, Griffiths, Suzanne, Barbour
openaire +2 more sources
Lipoprotein apheresis to treat elevated lipoprotein (a) [PDF]
Journal of Lipid Research, 2016 An elevated plasma concentration of lipoprotein (a) [Lp(a)] is an independent risk factor for cardiovascular disease. Life style modification and currently available drugs either fail to effectively lower plasma Lp(a) levels or do not result in clinical benefit. However, lipoprotein apheresis is very efficient in decreasing Lp(a) concentrations.
Elisa, Waldmann, Klaus G, Parhofer
openaire +2 more sources
The physiopathology of lipoprotein a
Frontiers in Bioscience, 2010 Lipoprotein(a) (also called Lp(a)) is a lipoprotein subclass. Different studies have identified Lp(a) as a putative risk factor for atherosclerotic diseases such as coronary artery disease and stroke. The physiological role of Lp(a) in humans is still unclear, but it seems that individuals with low concentrations of plasma Lp(a) manifest no deficiency ...
GALVANO, Fabio +7 more
openaire +3 more sources
Platelets, 1994 Sir, Malle and Sattler's excellent review links lipids with the release of serotonin from platelets.' It is therefore, of interest that correlations between serum cholesterol and intraplatelet/plasma serotonin concentrations have been reported.'-* Moreover, reducing serum cholesterol and low density lipoprotein (LDL) concentrations normalised ...
D P, Mikhailidis +3 more
openaire +2 more sources
Lipoprotein(a): An Enigmatic Sheep in the Lipoprotein Herd.
JACC. Basic to translational science, 2020 [Figure: see text]
Shapiro, Michael D., Fazio, Sergio
openaire +2 more sources
Evolving lipoprotein risk factors: lipoprotein(a) and oxidized low-density lipoprotein [PDF]
Clinical Chemistry, 1998 Abstract Cardiovascular disease is the leading cause of morbidity and mortality in Westernized populations. Evolving lipoprotein risk factors include LDL oxidation and lipoprotein(a) [lp(a)]. Several lines of evidence support a role for oxidatively modified LDL in atherogenesis and its in vivo existence.
openaire +2 more sources
Current Opinion in Lipidology, 2011 Lipoprotein glomerulopathy is a rare disorder characterized by proteinuria, renal insufficiency and disturbances in lipoprotein metabolism closely related to those observed in type III hyperlipidemia. Rare mutations in apolipoprotein E (apoE) gene may contribute to the pathogenesis of the disease.
Tsimihodimos, V., Elisaf, M. S.
openaire +3 more sources